The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles
Xueli Li(U.S. National Science Foundation), Xiaomei Zhang(The University of Texas MD Anderson Cancer Center), Yu Pan(U.S. National Science Foundation), Fang Lv(Liaoning Normal University), Liping Wang(Shenzhen Second People's Hospital), Li Wang(Northwestern University), Xiaman Huang(U.S. National Science Foundation)
Cited by 100
Related Papers
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
miRTarBase update 2022: an informative resource for experimentally validated miRNA–target interactions
|Nucleic Acids Research|2021|1k
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415
Luteolin-loaded solid lipid nanoparticles synthesis, characterization, & improvement of bioavailability, pharmacokinetics in vitro and vivo studies
|Journal of Nanoparticle Research|2014|128
CircCEMIP promotes anoikis-resistance by enhancing protective autophagy in prostate cancer cells
|Journal of Experimental & Clinical Cancer Research|2022|115